Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort

Mukta Arora, Michael T. Hemmer, Kwang Woo Ahn, John P. Klein, Corey S. Cutler, Alvaro Urbano-Ispizua, Daniel R. Courie, Amin M. Alousi, Robert Peter Gale, Yoshihiro Inamoto, Daniel J. Weisdorf, Peigang Li, Joseph H. Antin, Brian J. Bolwell, Michael Boyiadzis, Jean-Yves Cahn, Mitchell S. Cairo, Luis M. Isola, David A. Jacobsohn, Madan JagasiaThomas R. Klumpp, Effie W. Petersdorf, Stella Santarone, Harry C. Schouten, John R. Wingard, Stephen R. Spellman, Steven Z. Pavletic, Stephanie J. Lee, Mary M. Horowitz, Mary E. D. Flowers*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

19 Citations (Web of Science)


We previously reported a risk score that predicted mortality in patients with chronic graft-versus-host disease (CGVHD) after hematopoietic stem cell transplantation (HCT) between 1995 and 2004 and reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We sought to validate this risk score in an independent CIBMTR cohort of 1128 patients with CGVHD who underwent transplantation between 2005 and 2007 using the same inclusion criteria and risk score calculations. According to the sum of the overall risk score (range, 1 to 12), patients were assigned to 4 risk groups (RGs): RG1 (0 to 2), RG2 (3 to 6), RG3 (7 to 8), and RG4 (9 to 10). RG3 and RG4 were combined, as RG4 accounted for only 1% of the total cohort. Cumulative incidences of nonrelapse mortality (NRM) and probability of overall survival were significantly different between each RG (all P <.01). NRM and overall survival at 5 years after CGVHD for each RG were 17% and 72% in RG1, 26% and 53% in RG2, and 44% and 25% in RG3, respectively (all P <.01). Our study validates the prognostic value of the CIBMTR CGVHD RGs for overall survival and NRM in a contemporary transplantation population. The CIBMTR CGVHD RGs can be used to predict major outcomes, tailor treatment planning, and enroll patients in clinical trials. American Society for Blood and Marrow Transplantation.
Original languageEnglish
Pages (from-to)640-645
JournalBiology of Blood and Marrow Transplantation
Issue number4
Publication statusPublished - Apr 2015


  • Chronic graft-versus-host disease (CGVHD)
  • Risk score
  • Nonrelapse mortality

Cite this